Mandate

Vinge advises EQT Infrastructure and Meine Radiologie / Blikk in connection with the acquisition of Aleris’ radiology business

Vinge advises EQT Infrastructure and its portfolio companies Meine Radiologie Holding GmbH and Blikk Holding GmbH in connection with the acquisition of Aleris’ radiology business.

The acquisition includes the full operation of the business area radiology, with 22 units in Sweden and 14 in Norway as well as teleradiology operations in the Baltics, which together carry out more than 1 million radiology exams annually across a broad range of diagnostic imaging modalities.

The acquisition is subject to approval from applicable competition authorities.

Vinge’s team consisted of partner Daniel Rosvall together with Carl Sander, Elsie Nassar, Clara Sohlberg and Ebba Nyberg (M&A), Sam Fakhraie Ardekani (Commercial Agreements), Benjamin Vafaeian (Banking and Financing), Christoffer Nordin (Regulatory and permits), Ulf Pyk (Real Estate), Tove Lövgren Frisk (Compliance), Gustav Lindgren (Employment), Lisa Hörnqvist and Karolina Fuhrman (IT and GDPR), Jolene Reimerson (Separation), Emma Gustavsson (IPR) and Ellinor Gyllenhammar (Project and VDR Assistant).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025